Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 289

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 289
---
   |
| Issuance of January 2024 Warrants |     |   |    480,004 |   |
| Exercise of warrants              |     |   |   (562,879 | ) |
| Changes in fair value of warrants |     |   |   (707,802 | ) |
| Balance as of October 31, 2024    |     | $ |  3,519,702 |   |
| Exercise of warrants              |     |   |    (21,921 | ) |
| Change in fair value of warrants  |     |   | (1,319,081 | ) |
| Balance as of July 31, 2025       |     | $ |  2,178,700 |   |

F-49 CLEARMIND MEDICINE INC. Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended July 31, 2025 and 2024 (Expressed in United States Dollars) (Unaudited)

| 6. | Share Capital |

| a. | The Company’s authorized share capital is unlimited common shares without par value share. As of July 31, 2025, 5,379,441 (October 31, 2024 - 4,265,186) common shares were issued and outstanding. |

| (i) | During the nine months ended July 31, 2025, the Company issued 803,867 common shares in respect of restricted share units (“RSUs”) that had been fully vested. The RSUs had an aggregate fair value of $964,836 at the time of issuance. |

| (ii) | Between December 16, 2024, and December 27, 2024, April 2023 Warrants, September 2023 Warrants and January 2024 Warrants were exercised into 310,388 shares, resulting in gross proceeds of $441,577. |

| (i) | On November 6, 2023, 45 common shares with a fair value of $117 were issued to providers of investor services in payment of services. |

| (ii) | During the three months ended January 31, 2024, April 2023 Warrants and September 2023 Warrants were exercised for 1,062,188 shares, resulting in gross proceeds of $3,498,032. |

| (iii) | On January 16, 2024,